Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 5/20 | 0.40 |
| ▸ | MMP8 | P22894 | 4/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 10/20 | 0.40 |
| ▸ | MMP17 | Q9ULZ9 | 3/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22824347 | 0.89 | CNR2 (0.46) | PKMNPC1RAB9ACNR2MMP14 | |
| SCHEMBL10308970 | 0.83 | PKM (0.49) | PKMMMP14MMP8MMP13MMP17 | |
| SCHEMBL24597279 | 0.82 | PKM (0.45) | PKMMMP14MMP8MMP13MMP17 | |
| SCHEMBL21384021 | 0.82 | PKM (0.49) | PKMMMP14MMP8MMP13MMP17 | |
| SCHEMBL9609772 | 0.79 | GRM2 (0.47) | PKMGRM2 | |
| SCHEMBL15332913 | 0.79 | PKM (0.43) | PKMMMP14MMP8MMP13MMP17 | |
| SCHEMBL20704738 | 0.79 | PKM (0.43) | PKMNPC1RAB9AMMP14MMP8 | |
| SCHEMBL15118488 | 0.79 | PKM (0.43) | PKMCNR2MMP14MMP8MMP13 | |
| SCHEMBL12264183 | 0.79 | HTR2C (0.45) | PKMMMP14MMP8MMP13MMP17 | |
| SCHEMBL13432029 | 0.79 | PKM (0.47) | PKMCNR2MMP14MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180201602-A1 | VICINAL PRIMARY DIAMINES ASSOCIATED WITH METAL AND/OR FREE RADICAL CHELATION MOTIFS, AND ACTIVE AGAINST CARBONYL AND OXIDATIVE STRESS, AND USE THEREOF | UNIVERSITE AMIENS PICARDIE JULES VERNE (FR) | 2018-07-19 | — | — | US | disclosed |
| US-8063055-B2 | Substituted pyridone compounds and methods of use | AMGEN INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100160312-A1 | Substituted Pyridone Compounds and Methods of Use | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-7700607-B2 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2010-04-20 | — | — | US | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20080249090-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080081817-A1 | Nitrogenous Fused Bicyclic Compound | TANABE SEIYAKU CO., LTD. (JP) | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | CCR4, CCR1, HRH4 | PKM 4685/4885NPC1 2092/4885RAB9A 3905/4885 |
| US-20100160312-A1 | Substituted Pyridone Compounds and Methods of Use | KIT, CMA1, C3AR1 | PKM 703/4885NPC1 3253/4885RAB9A 2243/4885 |
| US-20180201602-A1 | VICINAL PRIMARY DIAMINES ASSOCIATED WITH METAL AND/OR FREE RADICAL CHELATION MOTIFS, AND ACTIVE AGAINST CARBONYL AND OXIDATIVE STRESS, AND USE THEREOF | CAT, GPX1, AOC1 | PKM 1656/4885NPC1 4414/4885RAB9A 1872/4885 |
| US-20080249090-A1 | Substituted pyridone compounds and methods of use | KIT, CMA1, C3AR1 | PKM 703/4885NPC1 3253/4885RAB9A 2243/4885 |
| US-20080081817-A1 | Nitrogenous Fused Bicyclic Compound | KCNH2, KCNN2, KCNN1 | PKM 1431/4885NPC1 500/4885RAB9A 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.